131 related articles for article (PubMed ID: 4439501)
61. B.C.G. in malignant melanoma.
Baker MA; Taub RN
Lancet; 1973 May; 1(7812):1117-8. PubMed ID: 4122031
[No Abstract] [Full Text] [Related]
62. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
63. Intralesional BCG application in malignant melanoma.
Sopková B; Kolár V
Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
[TBL] [Abstract][Full Text] [Related]
64. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM
N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001
[No Abstract] [Full Text] [Related]
65. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
[No Abstract] [Full Text] [Related]
66. Re-inventing intratumoral immunotherapy for melanoma.
Triozzi PL; Tuthill RJ; Borden E
Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
[TBL] [Abstract][Full Text] [Related]
67. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
68. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
Bilgi C; Brown NE; McPherson TA; Lentle B
Chest; 1979 Jun; 75(6):685-7. PubMed ID: 436519
[TBL] [Abstract][Full Text] [Related]
69. Does immunotherapy have any value in the treatment of malignant melanomas?
Roenigk HH
J Dermatol Surg Oncol; 1979 Feb; 5(2):132-3. PubMed ID: 762297
[TBL] [Abstract][Full Text] [Related]
70. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
[TBL] [Abstract][Full Text] [Related]
71. Malignant melanoma.
Lichtenfeld JL
Med Clin North Am; 1977 Sep; 61(5):1013-25. PubMed ID: 330971
[No Abstract] [Full Text] [Related]
72. Effectiveness of systemic BCG therapy in advanced melanoma.
El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
[TBL] [Abstract][Full Text] [Related]
73. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
74. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
75. Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma.
Plesnicar S; Rudolf Z
Cancer; 1982 Sep; 50(6):1100-6. PubMed ID: 7104950
[TBL] [Abstract][Full Text] [Related]
76. Adjuvant combination immunotherapy (BCG and levamisole) in malignant melanoma.
Dandapat MC; Mohapatra SK; Patra SK
Indian J Cancer; 1985 Jun; 22(2):100-7. PubMed ID: 3842124
[No Abstract] [Full Text] [Related]
77. BCG and cancer.
Bast RC; Zbar B; Borsos T; Rapp HJ
N Engl J Med; 1974 Jun; 290(26):1458-69. PubMed ID: 4598691
[No Abstract] [Full Text] [Related]
78. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
79. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
